Home Cart Sign in  
Chemical Structure| 5300-03-8 Chemical Structure| 5300-03-8

Structure of 9-cis-Retinoic acid
CAS No.: 5300-03-8

Chemical Structure| 5300-03-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AGN 192013 is a natural ligand which binds and activates the RARs.

Synonyms: Alitretinoin; NSC 659772; Panrexin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 9-cis-Retinoic acid

CAS No. :5300-03-8
Formula : C20H28O2
M.W : 300.44
SMILES Code : CC(/C=C/C=C(\C=C\C1=C(CCCC(C)1C)C)C)=C\C(O)=O
Synonyms :
Alitretinoin; NSC 659772; Panrexin
MDL No. :MFCD00270072

Safety of 9-cis-Retinoic acid

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H335-H360
Precautionary Statements:P201-P302+P352-P305+P351+P338-P308+P313

Isoform Comparison

Biological Activity

Description
9-cis-Retinoic acid (ALRT1057), a derivative of vitamin A, acts as a potent agonist for RAR/RXR. It induces apoptosis, regulates the cell cycle, and exhibits anticancer, anti-inflammatory, and neuroprotective properties[1][2][3][4][5].

In Vitro:

Cell Line
Concentration Treated Time Description References
human lymphatic endothelial cells (LECs) 1 µM 24 h promotes LEC migration Circulation. 2012 Feb 21;125(7):872-82
human lymphatic endothelial cells (LECs) 1 µM 48 h promotes LEC proliferation Circulation. 2012 Feb 21;125(7):872-82
Rat hepatic stellate cells 0.01, 0.1, 1 µM 48, 72, 96 h To examine the influence of 9-cis retinoic acid on extracellular matrix production and proliferation of activated hepatic stellate cells. Results showed that 9RA increased procollagen I mRNA 1.9-fold but did not affect other matrix proteins. Gut. 1999 Jul;45(1):134-42
Cultured human mesangial cells (CHMC) 1 μM 24 h To study the inhibitory effect of 9-cRA on monocyte adhesion to FCS-stimulated CHMC. Results showed that 1 μM 9-cRA significantly inhibited monocyte adhesion. Br J Pharmacol. 2000 Dec;131(8):1673-83
Cultured human mesangial cells (CHMC) 10 nM 24 h To study the preventive effect of 9-cRA on H2O2-induced CHMC death. Results showed that 10 nM 9-cRA significantly prevented H2O2-induced cell death. Br J Pharmacol. 2000 Dec;131(8):1673-83
Cultured human mesangial cells (CHMC) 10 nM to 100 nM 24 h To study the inhibitory effect of 9-cRA on FCS-induced CHMC proliferation. Results showed that 9-cRA dose-dependently inhibited FCS-induced CHMC proliferation at concentrations ranging from 10 nM to 100 nM. Br J Pharmacol. 2000 Dec;131(8):1673-83
A818-4 pancreatic adenocarcinoma cells 500 nM 6 days Did not induce apoptosis Br J Cancer. 2002 Aug 27;87(5):555-61
AsPc-1 pancreatic adenocarcinoma cells 500 nM 6 days Induced apoptosis Br J Cancer. 2002 Aug 27;87(5):555-61
T3M-4 pancreatic adenocarcinoma cells 500 nM 6 days Induced apoptosis, decreased Bcl-2/Bax ratio Br J Cancer. 2002 Aug 27;87(5):555-61
BxPc-3 pancreatic adenocarcinoma cells 500 nM 6 days Induced apoptosis, decreased Bcl-2/Bax ratio Br J Cancer. 2002 Aug 27;87(5):555-61

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude rats Human neuroblastoma xenograft model Oral 2 mg/day or 2.5 mg twice daily Once or twice daily for 10-12 days Evaluate the anti-tumor effects and toxicity of 9-cis-retinoic acid. Results showed that 2.5 mg twice daily significantly reduced tumor volume at day 10 but did not significantly reduce tumor weight. Br J Cancer. 2001 Dec 14;85(12):2004-9
Mice Mouse tail lymphedema model Intraperitoneal injection 0.8 mg/kg Daily for 32 days 9-cisRA significantly reduced tail lymphedema and promoted lymphatic vessel regeneration in mice Circulation. 2012 Feb 21;125(7):872-82

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00002439 Sarcoma, Kaposi|HIV Infections COMPLETED - -
NCT00002188 Sarcoma, Kaposi|HIV Infections PHASE2 COMPLETED - -
NCT01261923 Hepatic Insufficiency PHASE1|PHASE2 COMPLETED 2025-08-11 Gentofte Hospital, Hellerup, 2... More >>900, Denmark Less <<
NCT01407679 Lupus Erythematosus, Cutaneous PHASE2 TERMINATED 2025-04-14 Department of Dematology, Univ... More >>ersity Hospital, Mannheim, Baden-Wuerttemberg, 68167, Germany|Department of Dermatology, Ludwig-Maximilians University, Muenchen, Bayern, 80337, Germany|Department of Dermatology, University Hospital, Muenster, Westfalen, 48149, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.64mL

3.33mL

1.66mL

33.28mL

6.66mL

3.33mL

References

 

Historical Records

Categories